ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 0377 • ACR Convergence 2023

    Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis

    Melissa Mannion1, Monica Aswani2, Kristine Hearld2, Emily Smitherman2, Livie Huie3 and Jeffrey R Curtis4, 1University of Alabama at Brimingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Gardendale, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL

    Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
  • Abstract Number: 1658 • ACR Convergence 2023

    Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis

    Chrissy Bolton1, Christopher Mahony2, Charlotte Smith2, Vicky Alexiou3, Huong Nguyen3, Patricia Reis-Nisa2, Søren Lomholt4, Annie Hackland2, Sugrah Sultan5, Klaudia Kupiec3, Sunit Davda6, Charlene Foley6, Calliope Dendrou1, Elizabeth C Rosser7, Accelerating Medicines Partnership Program RA SLE Network8, Anna Helena Jonsson9, Fan Zhang10, Michael Brenner11, Soumya Raychaudhuri9, Christopher Buckley1, Manigandan Thyagarajan5, Zishan Shiekh5, Sandrine Compeyrot-Lacassagne6, Samantha Chippington6, Mark Coles1, Eslam Al-Abadi5, Andrew Filer2, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium12, Lucy R Wedderburn3 and Adam Croft2, 1University of Oxford, Oxford, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 4Aarhus University, Aarhus, Denmark, 5Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 6Great Ormond Street Hospital, London, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Brigham and Women's Hospital, Boston, MA, 10University of Colorado, Aurora, CO, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 12MRC, Birmingham, United Kingdom

    Background/Purpose: Understanding the unique and shared pathogenic processes between childhood-onset and adult-onset inflammatory arthritides is needed to guide more effective drug development and their application…
  • Abstract Number: 0358 • ACR Convergence 2023

    Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort

    Esraa Eloseily1, Autumn Clark1, Min-Lee Chang2, MaryEllen Riordan3, alan Russell4, Marc Natter5, Sherry Thornton6, Yukiko Kimura7 and Grant Schulert1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Boston Children's Hospital, Boston, MA, 3Hackensack Meridian Health, Hackensack, NJ, 4Duke Clinical Research Institute, Duke, NC, 5Harvard Medical School, Boston, MA, 6Cincinnati Children's Hospital, Cincinnati, OH, 7Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem with urgent unmet needs including prevalence, pathogenesis, disease…
  • Abstract Number: 0378 • ACR Convergence 2023

    Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment

    Remco Erkens1, Laura Huber1, Anouk Verwoerd1, Greta Rogani1, Dieneke Schonenberg-Meinema2, Merlijn van den Berg2, Wineke Armbrust3, Elizabeth Legger4, Sylvia Kamphuis5, Ellen Schatorjé6, Esther Hoppenreijs7, Joost Swart8, Marc Jansen1, Jorg van Loosdregt1 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, 3University Medical Hospital Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands, 5Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, 6University Medical Center Radboud, Nijmegen, Netherlands, 7Radboud University Medical Center, Nijmegen, Netherlands, 8Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe inflammatory disease with auto-inflammatory characteristics. The introduction of targeted biologic therapies has revolutionized the treatment and…
  • Abstract Number: 1660 • ACR Convergence 2023

    Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways

    Mariana Correia Marques1, Zuoming Deng2, Navid Chowdhury2, Elizabeth Schmitz3, Alana Platukus4, Stephen Brooks5, Carol Lake2, Ly-Lan Bergeron2, Michelle Millwood2 and Michael Ombrello6, 1National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, 5Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD

    Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…
  • Abstract Number: 0360 • ACR Convergence 2023

    Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial

    Bastiaan van Dijk1, Sytske Anne Bergstra1, Merlijn van den Berg2, Dieneke Schonenberg-Meinema2, Lisette van Suijlekom-Smit2, Marion van Rossum3, Yvonne Koopman4, Rebecca Ten Cate1, CF Allaart1, Danielle Brinkman1 and Petra Hissink Muller1, 1Leiden University Medical Center, Leiden, Netherlands, 2Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam Rheumatology and Immunology Center | Reade, Amstelveen, Netherlands, 4HagaZiekenhuis Juliana Children's Hospital, The Hague, Netherlands

    Background/Purpose: The relation between etanercept dose and clinical outcomes of juvenile idiopathic arthritis (JIA) is unclear. Most studies only evaluated doses up to 0.8 mg/kg/week…
  • Abstract Number: 0379 • ACR Convergence 2023

    Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation

    Alba Maria Torrat Noves1, Rebeca Perpiñan Perez2, Jose Ivorra Cortes1, Elena Grau Garcia1, Daniel Ramos Castro1, Pablo Francisco Muñoz Martínez3, Laura Mas Sanchez4, Carmen Riesco Barcena1, Anderson Victor Huaylla Quispe1, Samuel Leal Rodriguez1, Belen Villanueva Mañez1, Iago Alcantara Alvarez1, Isabel Martinez Cordellat1, Luis Gonzalez Puig1, Rosa Negueroles Albuixech1, Jose Eloy Oller Rodriguez1, Elvira Vicens Bernabeu1, Ernesto Tovar Sugrañes1, Marta De la Rubia Navarro4, Hikmat Charia1, Ines Canovas Olmos1, Carmen Najera Herranz1 and Jose Andres Roman Ivorra5, 1Rheumatology Department. HUP La Fe, Valencia, Spain, 2Universidad Catolica de Valencia San Vicente Martir, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Sagunto, Spain, 4Rheumatology Department. HUP La Fe, Valéncia, Spain, 5Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a group of chronic arthritis that begin in childhood. According to the International League of Associations for Rheumatology (ILAR)…
  • Abstract Number: 1662 • ACR Convergence 2023

    Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

    Jemy Varghese1, Scott Canna1, Emily Landy2, Laurence Eisenlohr1, Elise Peauroi3, Vinh Dang1, Anastasia Frank-Kamenetskii4 and Jeremy Morrissette5, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4CHOP/UPENN, Philadelphia, PA, 5University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and…
  • Abstract Number: 0031 • ACR Convergence 2023

    A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes

    Kaiyu Jiang1, tao liu2, Ryan Tewhey3, Susan Kales3, Yungki Park4 and James N Jarvis5, 1University at Buffalo, Buffalo, NY, 2Roswell Park Cancer Institute, Buffalo, NY, 3Jackson Laboratories, Bar Harbor, ME, 4University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY, 5University at Buffalo Jacobs School of Medicine, Buffalo, NY

    Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive disease risk…
  • Abstract Number: 0361 • ACR Convergence 2023

    Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience

    Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA

    Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
  • Abstract Number: 0758 • ACR Convergence 2023

    Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease

    STEPHANE MITROVIC1, Arianna De Matteis2, Sara Bindoli3, Fabrizio De Benedetti4, Bruno Fautrel5, Loreto Carmona6 and On Behalf Of The Eular/PreS QoC011 Task Force Member7, 1Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, 4Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, 5Sorbonne Université APHP, Paris, France, 6Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 7EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are part of the non-familial (sporadic) systemic inflammatory disorders and are frequently mentioned as…
  • Abstract Number: 1706 • ACR Convergence 2023

    Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis

    Claudia Harris1, Maria Taylor2, Ki Pui Lam2, Indu Raman3, Chengsong Zhu3, Pui Lee1, Peter Nigrovic4, Erin Janssen5, Jing Cui6 and Lauren Henderson4, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Immunology, Boston Children’s Hospital, Boston, MA, 3Department of Immunology, Microarray & Immune Phenotyping Core Facility, University of Texas, Southwestern Medical Center, Dallas, TX, 4Boston Children's Hospital, Boston, MA, 5Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A subset of children with oligoarticular juvenile idiopathic arthritis (oligo JIA) who are anti-nuclear antibody (ANA) positive are known to have dysregulated T cell-B…
  • Abstract Number: 0035 • ACR Convergence 2023

    Using Genotyping and Functional Data from Monocytes to Identify Risk-Driving SNPs on JIA Risk Haplotypes

    Emma Haley1, gilad Barshad2, Adam He2, Edward J Rice3, Elizabeth Crinzi1, Marc Sudman4, Susan Thompson5, Charles G Danko3 and James N Jarvis6, 1Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 2Cornell University, Ithaca, NY, 3Baker Institute of Animal Health Cornell University, Ithaca, NY, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Blue Ash, OH, 6University at Buffalo Jacobs School of Medicine, Buffalo, NY

    Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive disease risk…
  • Abstract Number: 0362 • ACR Convergence 2023

    Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis

    Danielle Bullock1, Ilir Agalliu2, Evin Rothschild2, Kaveh Ardalan3, Erica Lawson4, Natoshia Cunningham5, William Soulsby4, Nicole Reitz6, Laura Bouslaugh7, Anna Diggs8, Elizabeth Kessler9, Sara Kramer1, Bhupinder Nahal4, Cassandra Davis10, Ashley Kemp1, Riley O'Connor1, Tiffany Chinn4, Kathy Nguyen4, Paige Hill1 and Tamar Rubinstein11, 1University of Minnesota, Minneapolis, MN, 2Albert Einstein College of Medicine, Bronx, NY, 3Duke University School of Medicine, Durham, NC, 4University of California San Francisco, San Francisco, CA, 5Michigan State University, Grand Rapids, MI, 6CARRA, Allendale, MI, 7CARRA, Washington, DC, 8CARRA, Tipton, MO, 9Spectrum Health, Grand Rapids, MI, 10University of Utah, Salt Lake City, UT, 11Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY

    Background/Purpose: Adverse childhood events (ACEs) are common in children. ACEs are various stressors, including, but not limited to parental incarceration or food and housing insecurity.…
  • Abstract Number: 0761 • ACR Convergence 2023

    EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)

    Bruno Fautrel1, STEPHANE MITROVIC2, Arianna De Matteis3, Sara Bindoli4, Jordi Anton5, Alexandre Belot6, Claudia Bracaglia3, Tamas Constantin7, Lorenzo Dagna8, Alessandro de Bartolo9, Eugen Feist10, Dirk Foell11, Marco Gattorno12, Sophie Georgin-Lavialle13, Roberto Giacomelli14, Alexei Grom15, Yvan Jamilloux16, Katerina Laskari17, Calin Lazar18, Francesca Minoia19, Peter Nigrovic20, Filipa Oliveira Ramos21, Seza Ozen22, Pierre Quartier Dit Maire23, Piero Ruscitti24, Erdal Sag25, Sinisa Savic26, Marie-Elise Truchetet27, Sebastiaan Vastert28, Tanita Wilhelmer29, Carine Wouters30, Loreto Carmona31 and Fabrizio De Benedetti32, 1Sorbonne Université APHP, Paris, France, 2Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, 3IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 4Rheumatology Unit, department of Medicine,University of Padova, Padova, Italy, 5Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, 6Hospices Civils de Lyon, Collonges au mont d'or, France, 7Semmelweis University, Budapest, Hungary, 8Ospedale San Raffaele, Milano, Italy, 9PReS Patient Research Partner, Milan, Italy, 10Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 11University Hospital Münster, Münster, Germany, 12UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 13AP-HP, Tenon hospital, Paris, France, 14Policlinico Universitario Campus Bio-Medico, Roma, Italy, 15Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 16Hospices Civils de Lyon, Lyon, France, 17Athens University Medical School, Athens, Greece, 18University of Medicine and Pharmacy, Cluj-Napoca, Romania, 19Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 20Boston Children's Hospital, Boston, MA, 21Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, 22Hacettepe University Medical Faculty, Ankara, Turkey, 23Necker Hospital, Paris Cedex 15, France, 24University of L'Aquila, L'Aquila, Italy, 25Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 26Leeds University, Leeds, United Kingdom, 27Bordeaux University Hospital, Bordeaux, France, 28University Medical Center Utrecht, Utrecht, Netherlands, 29EULAR Patient Research Partner, Bludenz, Austria, 30Leuven University, Leuven, Belgium, 31Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 32Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) are supposed to be age counterparts of the same disease, but no consensus has…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology